U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H27FN4O2.C6H12O2
Molecular Weight 526.6428
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RISPERIDONE HEXANOATE

SMILES

CCCCCC(O)=O.CC1=C(CCN2CCC(CC2)C3=NOC4=C3C=CC(F)=C4)C(=O)N5CCCCC5=N1

InChI

InChIKey=KBFKXAXGRPWQON-UHFFFAOYSA-N
InChI=1S/C23H27FN4O2.C6H12O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22;1-2-3-4-5-6(7)8/h5-6,14,16H,2-4,7-13H2,1H3;2-5H2,1H3,(H,7,8)

HIDE SMILES / InChI

Molecular Formula C23H27FN4O2
Molecular Weight 410.4845
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H12O2
Molecular Weight 116.1583
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/risperidone.html http://www.wikidoc.org/index.php/Risperidone_(oral) http://www.rxlist.com/risperdal-drug.htm

Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors. It is FDA approved for the treatment of schizophrenia, bipolar mania, irritability associated with autistic disorder. Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. Vice versa, Fluoxetine, paroxetine, and other CYP 2D6 enzyme inhibitors increase plasma concentrations of risperidone. Common adverse reactions include increased mortality in elderly patients with dementia-related psychosis, cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis, neuroleptic malignant syndrome, tardive dyskinesia , metabolic Changes (hyperglycemia and diabetes mellitus, dyslipidemia, weight gain), hyperprolactinemia, orthostatic hypotension, leukopenia, neutropenia, agranulocytosis, potential for cognitive and motor impairment, seizures, dysphagia, priapism, disruption of body temperature regulation.

Originator

Curator's Comment: # Janssen Pharmaceutica N.V.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RISPERDAL

Approved Use

INDICATIONS & USAGE Risperidone tablets are indicated for the acute and maintenance treatment of schizophrenia [see Clinical Studies (14.1)

Launch Date

7.5712319E11
Primary
RISPERDAL

Approved Use

INDICATIONS & USAGE Risperidone tablets are indicated for the acute and maintenance treatment of schizophrenia [see Clinical Studies (14.1)

Launch Date

7.5712319E11
Primary
RISPERDAL

Approved Use

INDICATIONS & USAGE Risperidone tablets are indicated for the acute and maintenance treatment of schizophrenia [see Clinical Studies (14.1)

Launch Date

7.5712319E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
17 ng/mL
2 mg 2 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7.77 ng/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
83.1 ng × h/mL
2 mg 2 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
53.86 ng × h/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20 h
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.88 h
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
16 mg 1 times / day multiple, oral (max)
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
n = 198
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 198
Sources:
Disc. AE: Dizziness, Agitation...
AEs leading to
discontinuation/dose reduction:
Dizziness (1%)
Agitation (1%)
Somnolence (0.5%)
Hypotension postural (0.5%)
Tachycardia (0.5%)
Akathisia (1%)
Sources:
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
n = 448
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: adult
Population Size: 448
Sources:
Disc. AE: Parkinsonism, Somnolence...
AEs leading to
discontinuation/dose reduction:
Parkinsonism (0.4%)
Somnolence (0.2%)
Dizziness (0.2%)
Dystonia (0.2%)
SGOT increased (0.2%)
SGPT increased (0.2%)
Sources:
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Disc. AE: Dizziness, Nausea...
AEs leading to
discontinuation/dose reduction:
Dizziness (1.4%)
Nausea (1.4%)
Agitation (1.1%)
Parkinsonism (0.8%)
Somnolence (0.8%)
Dystonia (0.5%)
Abdominal pain (0.5%)
Hypotension postural (0.3%)
Tachycardia (0.3%)
Sources:
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 106
Health Status: unhealthy
Condition: Schizophrenia
Age Group: child
Population Size: 106
Sources:
Disc. AE: Somnolence, Dizziness...
AEs leading to
discontinuation/dose reduction:
Somnolence (2%)
Dizziness (2%)
Anorexia (1%)
Anxiety (1%)
Ataxia (1%)
Hypotension (1%)
Palpitation (1%)
Sources:
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 111
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: child
Population Size: 111
Sources:
Disc. AE: Somnolence, Nausea...
AEs leading to
discontinuation/dose reduction:
Somnolence (5%)
Nausea (3%)
Abdominal pain (2%)
Vomiting (2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypotension postural 0.5%
Disc. AE
16 mg 1 times / day multiple, oral (max)
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
n = 198
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 198
Sources:
Somnolence 0.5%
Disc. AE
16 mg 1 times / day multiple, oral (max)
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
n = 198
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 198
Sources:
Tachycardia 0.5%
Disc. AE
16 mg 1 times / day multiple, oral (max)
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
n = 198
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 198
Sources:
Agitation 1%
Disc. AE
16 mg 1 times / day multiple, oral (max)
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
n = 198
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 198
Sources:
Akathisia 1%
Disc. AE
16 mg 1 times / day multiple, oral (max)
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
n = 198
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 198
Sources:
Dizziness 1%
Disc. AE
16 mg 1 times / day multiple, oral (max)
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
n = 198
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 198
Sources:
Dizziness 0.2%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
n = 448
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: adult
Population Size: 448
Sources:
Dystonia 0.2%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
n = 448
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: adult
Population Size: 448
Sources:
SGOT increased 0.2%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
n = 448
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: adult
Population Size: 448
Sources:
SGPT increased 0.2%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
n = 448
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: adult
Population Size: 448
Sources:
Somnolence 0.2%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
n = 448
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: adult
Population Size: 448
Sources:
Parkinsonism 0.4%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
n = 448
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: adult
Population Size: 448
Sources:
Hypotension postural 0.3%
Disc. AE
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Tachycardia 0.3%
Disc. AE
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Abdominal pain 0.5%
Disc. AE
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Dystonia 0.5%
Disc. AE
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Parkinsonism 0.8%
Disc. AE
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Somnolence 0.8%
Disc. AE
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Agitation 1.1%
Disc. AE
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Dizziness 1.4%
Disc. AE
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Nausea 1.4%
Disc. AE
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Anorexia 1%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 106
Health Status: unhealthy
Condition: Schizophrenia
Age Group: child
Population Size: 106
Sources:
Anxiety 1%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 106
Health Status: unhealthy
Condition: Schizophrenia
Age Group: child
Population Size: 106
Sources:
Ataxia 1%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 106
Health Status: unhealthy
Condition: Schizophrenia
Age Group: child
Population Size: 106
Sources:
Hypotension 1%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 106
Health Status: unhealthy
Condition: Schizophrenia
Age Group: child
Population Size: 106
Sources:
Palpitation 1%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 106
Health Status: unhealthy
Condition: Schizophrenia
Age Group: child
Population Size: 106
Sources:
Dizziness 2%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 106
Health Status: unhealthy
Condition: Schizophrenia
Age Group: child
Population Size: 106
Sources:
Somnolence 2%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 106
Health Status: unhealthy
Condition: Schizophrenia
Age Group: child
Population Size: 106
Sources:
Abdominal pain 2%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 111
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: child
Population Size: 111
Sources:
Vomiting 2%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 111
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: child
Population Size: 111
Sources:
Nausea 3%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 111
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: child
Population Size: 111
Sources:
Somnolence 5%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 111
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: child
Population Size: 111
Sources:
Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
moderate [IC50 38.1 uM]
weak
no (co-administration study)
Comment: RISPERDAL did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP2D6
Page: 37.0
yes [IC50 15.78 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: Fluoxetine and paroxetine (CYP 2D6 inhibitors) have been shown to increase the plasma concentration of risperidone 2.5-2.8 fold and 3-9 fold, respectively
Page: 36.0
minor
minor
yes (co-administration study)
Comment: Carbamazepine co-administration with oral RISPERDAL decreased the steady-state plasma concentrations of risperidone by about 50%;
Page: 4.0
no
no
no
no
no
no
no
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Separation anxiety in children and adolescents treated with risperidone.
1999
Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.
1999 Feb
Tardive dystonia induced by risperidone.
1999 Jun
Case report of withdrawal syndrome after olanzapine discontinuation.
2000 Aug
A case of delayed NMS induced by risperidone.
2000 Feb
Further evidence that behavioral tests and neuropeptide mRNA and tissue level alterations can differentiate between typical and atypical antipsychotic drugs.
2000 Jul
Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
2000 Jun
Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
2000 Nov
The serotonin 5-HT(2A) receptor subtype does not mediate apomorphine-induced aggressive behaviour in male Wistar rats.
2000 Oct
Risperidone and tardive dyskinesia: a case of blepharospasm.
2000 Oct
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
2000 Oct
The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
2000 Sep
Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation.
2000 Summer
Olanzapine: an updated review of its use in the management of schizophrenia.
2001
Addition of risperidone to clozapine therapy in chronically psychotic inpatients.
2001 Feb
Priapism associated with polypharmacy.
2001 Feb
Weight gain with risperidone among patients with mental retardation: effect of calorie restriction.
2001 Feb
Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels.
2001 Feb
Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients.
2001 Feb
Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.
2001 Feb
Bodyweight gain with atypical antipsychotics. A comparative review.
2001 Jan
Clozapine therapy for a patient with a history of Hodgkin's disease.
2001 Jan
Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
2001 Jan 1
Consistency of atypical antipsychotic superiority to placebo in recent clinical trials.
2001 Jan 1
Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum.
2001 Jan 26
Effects of dopamine antagonists with different receptor blockade profiles on morphine-induced place preference in male mice.
2001 Jun
Effectiveness of ECT combined with risperidone against aggression in schizophrenia.
2001 Mar
Fixed-dosed risperidone in mania: an open experimental trial.
2001 Mar
Estrogen - a potential treatment for schizophrenia.
2001 Mar 1
Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
2001 Mar 1
Risperidone addition and psychotic exacerbation.
2001 Winter
Full remission of panic attacks in a schizophrenic patient after switching from haloperidol to risperidone.
2001 Winter
Patents

Sample Use Guides

Initial dosing is generally 2 mg/day. Dose increases should then occur at intervals not less than 24 hours, in increments of 1–2 mg/day, as tolerated, to a recommended dose of 4–8 mg/day. Effective dose range - 0.5-16 mg (disease dependent).
Route of Administration: Other
Measurement of ATP contents in the neuronal cell line showed significantly increased levels after a 24-h treatment with 25 microg/mL risperidone.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:04:55 UTC 2023
Edited
by admin
on Sat Dec 16 16:04:55 UTC 2023
Record UNII
FQ117R8W8H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RISPERIDONE HEXANOATE
Common Name English
HEXANOIC ACID, COMPD. WITH 3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)ETHYL)-6,7,8,9-TETRAHYDRO-2-METHYL-4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE
Systematic Name English
Code System Code Type Description
FDA UNII
FQ117R8W8H
Created by admin on Sat Dec 16 16:04:55 UTC 2023 , Edited by admin on Sat Dec 16 16:04:55 UTC 2023
PRIMARY
CAS
1587586-95-5
Created by admin on Sat Dec 16 16:04:55 UTC 2023 , Edited by admin on Sat Dec 16 16:04:55 UTC 2023
NON-SPECIFIC STOICHIOMETRY
PUBCHEM
70675271
Created by admin on Sat Dec 16 16:04:55 UTC 2023 , Edited by admin on Sat Dec 16 16:04:55 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY